Xeloda Black Box Warning Added Due toBleeding Risk with Blood Thinner Use

The new Xeloda warnings are part of a program reviewing cancer drugs which have been on the market for decades and may need label warning updates.

Federal drug regulators have placed a “black box” warning on Xeloda, indicating that the cancer drug may increase the bleeding risk when taken with a class of blood thinners known as vitamin K antagonists, like warfarin.

The new Xeloda label warning (PDF) was announced on January 17, in the Journal of the American Medical Association (JAMA).

The update comes as a result of an U.S. Food and Drug Administration (FDA) pilot program known as Project Renewal, which has the agency taking a look at cancer drugs that are several decades old, and may need their labels updated due to out-of-date formatting or have significant off-label uses.

Xeloda (capecitabine) is approved for the treatment of colorectal cancer and breast cancer. In the United States, the Roche medication was first approved by the FDA in 1998, and it is now also available as a generic. In 2013, the cancer drug was linked to a risk of  Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Some cases of the Xeloda skin reactions have resulted in death, Health Canada researchers warned.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

As a result of the recent investigation, the FDA added a new boxed warning, which is the most stringent warning the agency can require a drug to carry, indicating using Xeloda with a vitamin k antagonist blood thinner could increase the risk of bleeding.

“Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking XELODA concomitantly with oral vitamin K antagonists,” the new boxed warning states.

The new label warnings also include new and revised indications for colon, rectum, breast, gastrointestinal tract and pancreatic cancers. It also includes changes on dosing regimens.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns
Zimmer Biomet CPT Hip System Linked to Increased Risk of Thigh Bone Fractures, FDA Warns (Posted today)

The FDA has issued a safety communication warning that Zimmer Biomet CPT hip system femoral stems may increase the risk of femur fractures, calling for doctors to avoid its use when possible.

Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference
Change Healthcare Data Breach Lawyers Meeting Today With MDL Judge For Initial Status Conference (Posted yesterday)

The judge presiding over all Change Healthcare lawsuits filed in federal court is holding the first status conference of the litigation, which is expected to grow significantly as Change Healthcare data breach letters continue to be sent to impacted customers.

Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury
Angiodynamics LifePort Lawsuit Filed Over Risk of the Port Catheters Failing, Causing Severe Injury (Posted 2 days ago)

Complaint comes as a panel of federal judges are scheduled to hear oral arguments later this month, to determine whether all AngioDynamics port catheter lawsuits filed in U.S. District Courts nationwide should be centralized before one judge.